Novo Nordisk to end business tie-up with Dalim

Novo Nordisk Pharma Korea, a Korean Unit of Novo Nordisk in Demark, says it agreed to terminate its 25-year business relationship with Dalim Corporation over the local distribution of conventional human insulin preparations - Insuratard Human Insulin and Mixtard Human Insulin.

Under the agreement, Novo Nordisk will directly supply all of the existing preparations to its wholesalers from Apri...